Redlight Guide

Acne vulgaris

Red light therapy for acne

Evidence for red light therapy in acne vulgaris, including a meta-analysis and a small split-face RCT.

Study count

Cited source set includes 9 records, including 3 source(s) imported from the PlatinumLED news source inventory.

Evidence grade

moderate

Panel relevance

partially-replicable

Bottom line

This category is useful for consumer LED masks and handhelds, but should be framed as adjunctive acne care rather than a replacement for proven acne treatments.

Consensus: At-home red/blue LED acne devices have a positive evidence signal, while red-light-only evidence remains mixed and should not be presented as superior to conventional acne care.

What the studies found

  • The 2025 at-home LED meta-analysis found improvements in inflammatory lesions, noninflammatory lesions, and investigator global assessment versus control.
  • The 2021 red-light meta-analysis found no statistically significant superiority over conventional therapies for inflammatory, non-inflammatory, or total lesion outcomes.
  • A 2007 split-face RCT found significant improvement in inflammatory and non-inflammatory lesion counts versus the untreated control side.
  • A 2013 home-use 420/660 nm blue-red LED RCT reported lesion-count improvements over 4 weeks without severe adverse events.
  • A 2022 randomized trial found red and blue light had similar efficacy in mild-to-moderate acne, especially for inflammatory lesions.
  • Adverse events in the meta-analysis were generally mild or absent.
  • Platinum-sourced additions broaden the citation map; imported records need full-text review before converting them into stronger efficacy claims.

Dosage and timing

Wavelengths420, 630, 660, 670 nm
IrradianceNot settled
FluenceNot settled
Session timeOne home-use blue/red RCT used 2.5 minutes twice daily; another small red-only RCT used 15 minutes.
FrequencyVaried from frequent short home sessions to trial-specific office or device protocols.
DurationAt-home LED studies ranged from days to 12 weeks; representative RCTs used 4-8 weeks.
TimingNo strong time-of-day consensus.
Treatment areaAcne-affected facial skin.
Device typesPortable red LED devices and other red light acne devices.
NotesSeparate red light-only therapy from photodynamic therapy when writing.
  • No red-light-only consensus protocol emerges across the acne literature.
  • The strongest consumer-device evidence often uses combined blue/red LEDs rather than red alone.
  • The most panel-relevant red-only source used frequent short facial sessions, but it was small.
  • Protocol claims should distinguish mild-to-moderate acne from moderate-to-severe acne.
  • Imported records with missing protocol fields are not used as calculator presets.

Caveats

  • Acne can scar and may need medical treatment.
  • Some acne light literature involves blue light or photosensitizers, which should not be mixed into red-only claims.
  • A mixed meta-analysis should outweigh a single positive small trial in article conclusions.
  • Some added citations are indirect, mechanistic, animal, or specialist-device studies and should not be generalized to home panels.

Cited peer-reviewed sources

meta-analysis 6 included studies Evidence: moderate; direction: positive Panel relevance: partially-replicable Wavelengths: 630, 670, 414, 445 nm Dose/timing: Varied across at-home LED studies / 2 days to 12 weeks across included studies Area: Acne-affected facial skin Device: At-home or portable red and/or blue LED acne devices Source

Ershadi A, Barbieri JS. JAMA Dermatology. 2025.

A 2025 systematic review and meta-analysis focused specifically on at-home LED devices for acne vulgaris.

Source

meta-analysis 13 included studies Evidence: low; direction: mixed Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Varied by trial / Varied by trial Area: Acne-affected skin Device: Red light therapy devices; some acne literature overlaps with photodynamic therapy Source

Wu Y, Deng Y, Huang P, et al. Journal of Cosmetic Dermatology. 2021.

A meta-analysis of red light therapy for acne found no statistically significant superiority over conventional therapies.

Source

randomized-controlled-trial 28 participants Evidence: low; direction: positive Panel relevance: panel-replicable Wavelengths: Not reported Dose/timing: 15 min / Twice daily / 8 weeks Area: One side of the face Device: Portable red light-emitting device Source

Na JI, Suh DH. Dermatologic Surgery. 2007.

A small split-face randomized trial tested portable red LED phototherapy for mild-to-moderate acne.

Source

randomized-controlled-trial 35 participants Evidence: low; direction: positive Panel relevance: partially-replicable Wavelengths: 420, 660 nm Dose/timing: 2.5 min / Twice daily / 4 weeks, with follow-up to 12 weeks Area: Acne-affected facial skin Device: Home-use blue and red LED acne device Source

Kwon HH, Lee JB, Yoon JY, et al. British Journal of Dermatology. 2013.

A double-blind randomized home-use trial tested combination blue and red LED phototherapy for mild-to-moderate acne.

Source

randomized-controlled-trial Study count not extracted Evidence: low; direction: positive Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Not fully reported Area: Acne-affected skin Device: Red and blue light acne phototherapy devices Source

Li J, Li J, Zhang L, et al. Photodermatology, Photoimmunology & Photomedicine. 2022.

This randomized clinical study compared red and blue light therapy for mild-to-moderate acne vulgaris.

Source

meta-analysis Study count not extracted Evidence: moderate; direction: positive Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Varied across included skin therapy studies / Varied across included skin therapy studies Area: Skin Device: LED skin therapy devices Source

Ngoc LTN, Moon JY, Lee YC. Photodermatology, Photoimmunology & Photomedicine. 2023.

This systematic review and meta-analysis evaluated LED use for skin therapy and found statistically significant overall effects for red and blue LED light in acne treatment.

Source

other Study count not extracted Evidence: very-low; direction: mixed Panel relevance: partially-replicable Wavelengths: 415, 660 nm Dose/timing: Not extracted from Platinum intake metadata / Not extracted from Platinum intake metadata Area: Not extracted Device: Peer-reviewed source; device/protocol requires full-text review Source

Papageorgiou P, Katsambas A, Chu A. Br J Dermatol. 2000.

Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.

Source

animal-or-in-vitro Study count not extracted Evidence: indirect; direction: unclear Panel relevance: not-panel-replicable Wavelengths: Not reported Dose/timing: Not extracted from Platinum intake metadata / Not extracted from Platinum intake metadata Area: Not extracted Device: Peer-reviewed source; device/protocol requires full-text review Source

Gold MH, Andriessen A, Biron J, Andriessen H. J Clin Aesthet Dermatol. 2009.

Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.

Source

systematic-review Study count not extracted Evidence: low; direction: mixed Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Not extracted from Platinum intake metadata / Not extracted from Platinum intake metadata Area: Not extracted Device: Peer-reviewed source; device/protocol requires full-text review Source

Diogo MLG, Campos TM, Fonseca ESR, Pavani C, Horliana ACRT, Fernandes KPS, Bussadori SK, Fantin FGMM, Leite DPV, Yamamoto ÂTA, Navarro RS, Motta LJ. Sensors (Basel). 2021.

Imported from the PlatinumLED news source inventory as a peer-reviewed citation. This first-pass record preserves source metadata and needs full-text protocol extraction before it should be used for consumer dosing guidance.

Source

Last reviewed: 2026-06-15